Clinical Trials Logo

Seach Results for — “light therapy”

Transcranial Near-infrared Light Therapy for Mild-Moderate Alzheimer's Disease

The Safety and Efficacy of Transcranial Near-infrared Light in the Treatment of Mild-Moderate Alzheimer's Disease

The goal of this study is to explore the efficacy and safety of Near-infrared light Photobiomodulation in patients with mild-moderate Alzheimer's disease(AD). This study will employ a randomized,blind,parallel controlled approach.Qualified subjects were selected and randomized (experimental group: control group=1:1). The subjects who entered the experimental group received 30 minutes of near-infrared light therapy once a day, 6 times a week, for 16 weeks of continuous treatment; The subjects who entered the control group received 30 minutes of non near-infrared light irradiation once a day (false treatment), 6 times a week, for 16 weeks.

NCT06160908 — Alzheimer Disease
Status: Recruiting
http://inclinicaltrials.com/alzheimer-disease/NCT06160908/

Light Therapy in Parkinson's Disease

Light Therapy in Parkinson's Disease: a Prospective, Observational Study

The aim of this randomized controlled trial (RCT) is to clarify the effect of bright light therapy on motor symptoms and sleep disorders in patients with Parkinson's disease.

NCT06129942 — Parkinson Disease
Status: Recruiting
http://inclinicaltrials.com/parkinson-disease/NCT06129942/

Light Therapy Plus Exercise to Improve Motor, Non-Motor Symptoms and QoL in Parkinson's Disease

Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Effectiveness of Photobiomodulation With Exercise, to Enhance Motor, Cognition and the Quality of Life of Those With Parkinson's Disease

Parkinson's disease (PD) is a lifelong and progressive disease and is the second most common progressive neurodegenerative disease worldwide. This study will examine whether there are significant differences in motor (e.g., balance and gait) and non-motor (e.g., cognition, mood, smell & sleep ) symptoms and quality of life between the Real (active) at-home photobiomodulation (light therapy) combined with exercise group and the Placebo (sham) at-home photobiomodulation (light therapy) combined with exercise group. Each group (Real & Placebo) will include 30 participants; with moderate PD, ages 55-80. Three outcome measurement sessions will be conducted; at the study entry and the end of Weeks 1 & 4 after the last light therapy treatment. Exercise must have been part of the participant's routine before entering the study and will continue during and after the light therapy treatments have been completed.

NCT06036433 — Disease
Status: Recruiting
http://inclinicaltrials.com/disease/NCT06036433/

Flashed Light Therapy for Adolescents With ADHD and Delayed Sleep Timing

Flashed Light Therapy for Adolescents With ADHD and Delayed Sleep Timing

The primary aim of the present research project is to examine the feasibility, as measured by treatment perceptions, and tolerability, as measured by adherence and attrition, of two weeks of flashed light therapy alone followed by four weeks of daily flashed light therapy combined with four weekly videoconference-delivered cognitive behavioral therapy sessions targeting circadian rhythms and sleep in four adolescents aged 14 to 17 years with attention-deficit/hyperactivity disorder and delayed sleep-wake schedules.

NCT06036420 — ADHD
Status: Recruiting
http://inclinicaltrials.com/adhd/NCT06036420/

Efficacy and Safety of Near Infrared Light Therapy for Alzheimer's Disease

Efficacy and Safety of Near Infrared Light Therapy for Alzheimer's Disease

To explore the efficacy and safety of near infrared light therapy for Alzheimer's disease. Each subject will be numbered and their medical records will be established. The subjects will be randomly assigned to the treatment group or the control group for 30 minutes/day (5-6 days a week) for 4 months while the treatment group is active settings and the control group is sham settings.Follow-up visits will be conducted at 2 months, 4 months and 2 months after treatment. At each follow-up, scale assessment, blood, MRI, and EEG were observed

NCT06008639 — Mild to Moderate Alzheimer's Disease
Status: Enrolling by invitation
http://inclinicaltrials.com/mild-to-moderate-alzheimer-s-disease/NCT06008639/

Using Large-area Low-level Light Therapy for Treating Adhesive Capsulitis of the Shoulder

Using Large-area Low-level Light Therapy for Treating Adhesive Capsulitis of the Shoulder

Adhesive capsulitis, is a common problem characterized by the insidious onset of glenohumeral pain and limitation of shoulder motion in all planes. Clinically, frozen shoulder could be divided into freezing, frozen and thawing stage. The treatments of frozen shoulder are mainly conservative, including non-steroidal anti-inflammatory medications and physiotherapy. Due to debilitating pain at a certain stage and protracted clinical course, intra-articular corticosteroid injection in the early stages of idiopathic adhesive capsulitis has long been used to treat adhesive capsulitis with satisfactory result. However, intra-articular steroid injection still raise some controversy and is still considered too invasive for some patients. Low-level laser therapy (LLLT) is a safe and non-invasive alternative. LLLT can employ photo-biomodulation effects to help normalize cellular functions and is considered to have partial effect in many shoulder soft tissue disorders. Possible mechanisms include increasing adenosine triphosphate production, fibroblast activity and collagen synthesis. One prospective cohort study has shown that LLLT can be effective in the management of the early phase (less than 6 weeks of disease onset) of adhesive capsulitis of the shoulder in elderly who failed to respond to conventional physical therapy and nonsteroidal anti-inflammatory medications and improvement was found maintained up to 2 years. To this date, no randomized controlled study has been made to establish the possible role of LLLT as an adjuvant therapy on adhesive capsulitis. Also, no study has researched the effect of LLLT on patient with later stage/chronic phase of adhesive capsulitis. The objective of this paper is to report the clinical result of a study on the efficacy of LLLT as an add-on therapy in the management of adhesive capsulitis.

NCT06004609 — Adhesive Capsulitis of Shoulder
Status: Recruiting
http://inclinicaltrials.com/adhesive-capsulitis-of-shoulder/NCT06004609/

Effect of Bioptron Light Therapy on Dryness of Eyes in Postmenopausal Women

Effect of Bioptron Light Therapy on Dryness of Eyes in Postmenopausal Women

Dry eye disease (DED) is a growing public health concern affecting quality of life and visual function, with a significant socio-economic impact. It is more prevalent in the females and is being specifically in the menopausal and postmenopausal age group. Bioptron light therapy is efficient in the elimination of allergic reactions, signs and symptoms of dry eye improving capillary circulation, immunity stimulation, relieving pain and establishing balance of tissue electromagnetic field

NCT05964673 — Postmenopausal Women
Status: Recruiting
http://inclinicaltrials.com/postmenopausal-women/NCT05964673/

BioClock: Bright Light Therapy for Depressive Disorders

BioClock: Optimization, Working Mechanisms and Response Predictors of Bright Light Therapy for Depressive Disorders - a Multicentre Randomized Controlled Trial

Bright Light Therapy (BLT) is a proven treatment for depression in seasonal and non-seasonal depressive disorders, as well as bipolar disorder. To make BLT more effective and practical in clinical settings and tailor it to individual needs, it is necessary to optimize the treatment approach, understand how the treatment works, and identify patient characteristics that predict response. This clinical trial has three main goals: - Optimize the administration of BLT for patients with depressive episodes. - Gain a deeper understanding of the treatment mechanisms. - Determine which patients benefit the most from the treatment. The specific objectives are as follows: - Investigate whether additional treatments and interventions related to lifestyle and the biological clock can enhance the effects of BLT. - Examine how BLT influences the body's internal clock and sleep quality, and how these factors contribute to the outcomes. - Identify patient characteristics and behaviours that can predict treatment outcomes. - Develop a brain model to better understand the impact of BLT on the brain. In this study, patients will receive BLT with a light intensity of 10,000 lux for 30 minutes each morning over 5 consecutive days. The treatment duration will range from one to three weeks, depending on the improvement of depressive symptoms. Participants will be randomly assigned to one of three groups: - Home - Patients will receive BLT at home, following the standard guidelines for light therapy in the Netherlands. - LightCafé, fixed time: Patients will receive BLT in a café-like setting called the LightCafé, where the focus is not only on symptom improvement but also lifestyle enhancements and fostering social connections. The treatment time will be the same every day. - LightCafé, varying time: Patients will also receive BLT at the LightCafé, with treatment timing varying each day. Additionally, this group will wear glasses in the evening that filter blue light. The study includes a baseline phase of up to two weeks, a treatment phase of up to three weeks, and a three-month follow-up phase. Patients will wear a motion watch to assess sleep-wake behaviour and physical activity during the day. Additionally, they will wear a broach that measures their personal light exposure throughout the day. Eight one-minute questionnaires per day will be sent to the participants' smartphones to assess vitality, sleep, and mood during the treatment. Predictors of treatment response, such as clinical characteristics, sleep measures, circadian parameters, and light-related behaviours, will be evaluated at baseline. In a small group of patients, salivary melatonin curves will be assessed before and after treatment. MRI scans will provide insights into functional and structural brain changes following light therapy treatment.

NCT05958940 — Depression, Unipolar
Status: Not yet recruiting
http://inclinicaltrials.com/depression-unipolar/NCT05958940/

Impact of Bright Light Therapy on Prader-Willi Syndrome - PWS-LT

A Randomized, Double-Blind, Controlled Trial of Bright Light Therapy on All-Cause Excessive Daytime Sleepiness in Prader-Willi Syndrome

This is a placebo controlled clinical trial to assess the utility of light therapy as a sufficient treatment for excessive daytime sleepiness in patients with Prader-Willi Syndrome

NCT05939453 — Body Weight
Status: Recruiting
http://inclinicaltrials.com/body-weight/NCT05939453/

Bright Light Therapy for OSA - BrightDaysII

Bright Light Therapy for Residual Daytime Symptoms Associated With Obstructive Sleep Apnea

Persistent daytime symptoms of sleepiness in individuals with obstructive sleep apnea (OSA) who are using Continuous Positive Airway Pressure (CPAP) are associated with adverse long term medical and functional outcomes. Supplementary exposure to bright light has beneficial effects on sleep quality and daytime vigilance in healthy individuals and it has been increasingly applied in a variety of sleep and neuropsychiatric conditions. This study will explore the role of Bright Light Therapy (BLT), a well-established non-pharmacological intervention for circadian disturbances, for the treatment of residual daytime symptoms of OSA which do not respond to CPAP. BLT will be delivered via therapy glasses in a cross-over design, where each participant will be exposed to active treatment and sham treatment (4 weeks in each arm) in a randomized order. The hypothesis is that participants will demonstrate improvements in the variables of interest during the four-week active treatment portion of the eight-week crossover study, compared to the four-week sham treatment portion.

NCT05917119 — Obstructive Sleep Apnea
Status: Recruiting
http://inclinicaltrials.com/obstructive-sleep-apnea/NCT05917119/